Key Findings
A recent review published by MDPI offers an in-depth analysis of the complex physiological determinants that govern the oral absorption of therapeutic peptides. The review reaffirms the long-standing challenge of extremely low oral peptide bioavailability, typically less than 1%, clearly identifying enzymatic degradation, pH effects, gastrointestinal motility, the gut microbiota, and intercellular tight junctions as primary barriers inhibiting peptide uptake.
Technical / Clinical Details
- Low Bioavailability: The oral absorption of therapeutic peptides is severely limited, resulting in very low bioavailability, primarily due to their proteinaceous nature and instability within the harsh gastrointestinal environment. This instability is a key reason why injectable formulations remain predominant.
- Primary Physiological Barriers:
- Enzymatic Degradation: Proteases present in the stomach and small intestine (e.g., pepsin, trypsin) readily cleave peptide bonds, leading to the loss of therapeutic activity.
- pH Effects: The highly acidic environment of the stomach and fluctuating pH levels in the intestine can affect peptide stability and conformation, accelerating degradation.
- Motility: Peristaltic movements in the gastrointestinal tract reduce the residence time of drugs at absorption sites, decreasing absorption efficiency.
- Microbiota: The gut microbiome can also contribute to drug degradation by producing peptide-degrading enzymes.
- Tight Junctions: Tight junctions between intestinal epithelial cells severely restrict paracellular permeation of larger molecules like peptides.
- Limited Absorption Opportunities: Intriguingly, the review also highlights that these formidable barriers simultaneously present limited opportunities for peptide uptake under specific conditions, such as transport via specific transporters or transient opening of tight junctions by permeation enhancers.
Background & Context
Peptides are an attractive therapeutic modality due to their high target specificity, low toxicity, and potent efficacy. However, the formidable challenges of oral administration have been a significant impediment to their broader clinical application and market expansion. For improved patient convenience and adherence, the development of oral peptide formulations has long been considered a “holy grail” in the pharmaceutical industry. This review provides fundamental understanding essential for advancing oral delivery technologies.
This research is particularly crucial for fields like diabetes treatment, where there is a strong demand to transition from injectable to oral GLP-1 receptor agonists.
Strategic Significance & Outlook
The mechanisms elucidated in this review provide a critical foundation for designing novel drug delivery strategies for oral peptide formulations. Future technological developments, such as co-administration with protease inhibitors, pH-stabilized formulations, permeation enhancers, or encapsulation within nanocarriers, will be key to improving oral peptide bioavailability. Ultimately, these advancements are expected to enable more peptide-based medicines to be taken orally rather than via injection, significantly enhancing patient quality of life and expanding therapeutic access.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments